Patients With Refractory Crohn’s Disease Successfully Treated With Ustekinumab

Introduction: Ustekinumab is a new a biologic therapy targeting interleukin (IL)-12 and IL-23. It is currently approved for the treatment of psoriasis, but clinical trials have shown that it can induce and maintain remission in Crohn’s disease (CD). We aim to evaluate ustekinumab effectiveness in treatment of CD. Methods: A retrospective multicenter chart review was performed including patients with complicated, refractory CD started on...